NCT04776590

Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer

Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by Surgery for Thoracic Esophageal Squamous Cell Cancer: A Prospective, Single Arm, Pilot Study

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Neoadjuvant chemoradiotherapy is recommended as standard therapy for resectable esophageal cancer. The recurrence rate after surgery following neoadjuvant chemoradiotherapy is about 35%. Whether achieving pathological complete response after neoadjuvant chemoradiotherapy is significantly associated with recurrence after surgery. It is reported that immunotherapy combined with chemotherapy improved survival compared with chemotherapy alone in first line therapy of advanced esophageal cancer. We hypothesize that the addition of immunotherapy to neoadjuvant chemoradiotherapy is helpful to improving pathologic complete response and survival.

Conditions

• Esophagus Cancer
• Neoadjuvant Therapy

Interventions

Type	Name	Description
DRUG	Tislelizumab	neoadjuvant immunotherapy

Timeline

• Start date: 2021-01-28
• Primary completion: 2023-03-11
• Completion: 2024-12-15
• First posted: 2021-03-01
• Last updated: 2024-04-12

Locations

1 site across 1 country: China